Cover Image
市場調查報告書

生技仿製藥/生技學名藥(技術、種類、用途、服務、地區)的全球市場:規模、佔有率、全球趨勢、企業簡介、需求、考察、分析、調查、報告、機會、市場區隔、預測

Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020

出版商 Allied Market Research 商品編碼 310278
出版日期 內容資訊 英文 184 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生技仿製藥/生技學名藥(技術、種類、用途、服務、地區)的全球市場:規模、佔有率、全球趨勢、企業簡介、需求、考察、分析、調查、報告、機會、市場區隔、預測 Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020
出版日期: 2014年07月01日 內容資訊: 英文 184 Pages
簡介

生技仿製藥/生技學名藥,是智慧財產權即將結束的生技藥品的拷貝版,專利期結束成為市場主要促進要素。2014年末許多暢銷產品的專利預定將結束,預計地區的製藥企業的競爭將激化。2013年的生技仿製藥/生技學名藥市場規模是13億5,800萬美元,預計2020年年複合成長率成長60.8%達到350億3,200萬美元規模。

本報告提供全球生技仿製藥/生技學名藥市場相關調查分析、市場概要、各技術、種類、用途、服務、地區的考察、主要企業簡介等相關彙整。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義
  • 全球法規機關對生技仿製藥的各種方法
  • 生技仿製藥的安全性問題
  • 主要調查結果
  • 法規與回本方案
  • 生技仿製藥市場熱點為新興國家
  • 波特的五力分析
  • 價值鏈分析
  • 臨床試驗
  • 市場佔有率分析
  • 市場動態

第4章 全球生技仿製藥/生技學名藥市場:各技術

  • 單株抗體(MAb)技術
  • 重組的DNA技術(rDNA技術)
  • 層析法
  • 核磁共振(NMR)技術
  • 電泳
  • 質譜分析
  • 免疫印漬術
  • 生物檢測

第5章 全球生技仿製藥/生技學名藥市場:各產品種類

  • 重組的非糖化蛋白質
  • 重組的糖化蛋白質

第6章 全球生技仿製藥/生技學名藥市場:各用途

  • 血液疾病
  • 腫瘤疾病
  • 慢性自體免疫疾病
  • 生長激素缺乏症
  • 其他

第7章 全球生技仿製藥/生技學名藥市場:各類服務

  • 委託研究/製造服務
  • 臨床試驗

第8章 全球生技仿製藥/生技學名藥市場:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美/中東/非洲

第9章 主要產品和最近的活動:各地區

  • 美國
  • 歐洲
  • 印度
  • 韓國
  • 其他

第10章 企業簡介

  • Novartis (Sandoz)
  • Synthon Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • LG Life Sciences
  • Celltrion
  • Biocon
  • Hospira
  • Merck Serono (Merck Group)
  • Biogen idec Inc.
  • Genentech (Roche Group)

圖表

目錄
Product Code: PH 14162

Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the biosimilars market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players. For instance, patents for insulin glargine will expire by the end of this year, which would give an opportunity for the growth of insulin biosimilars market. Global biosimilars/follow-on-biologics market accounted for $1,358 million in 2013 and it is anticipated to generate $35,032 million by 2020, growing at a CAGR of 60.8% from 2014 to 2020.

Regulations for biosimilars plays a vital role in maintaining the viability and balance between original and biosimilar products. Various regulatory authorities, namely EMA and the U.S. FDA are actively regulating the biosimilars market. Regulations in the European union are considered benchmark around the world, as the guidelines proposed are most stringent for validation and commercialization of biosimilars. High profitability is the attractive aspect that is enticing companies to invest in the biosimilars industry.

Geographically, Biosimilars market is segmented into North America, Europe, Asia-Pacific and LAMEA. Due to favorable regulatory policies designed by the European Medical Association, the European market has been maximizing on the biosimilars market. Asia-Pacific and LAMEA market would witness a substantial rise in the use of biosimilars, as the demand for cost effective treatment is growing due to the prevalence of chronic diseases. Collaboration with local players would be a key opportunity that could be fully explored by the biosimilars manufacturers in developing economies. Many companies such as Amgen and Novartis are collaborating with Asian players to gain a foothold in the biopharmaceutical market.

Europe was the first region to draft guidelines for approval of biosimilars in 2006. Nevertheless, in 2008, the first biosimilars version of Granulocyte colony-stimulating factor (G-CSF) was introduced in the European Union under the regulatory guidance of European Medical Association (EMA). Currently, there are three biosimilar versions of G-CSF available in the European market, namely Ratiograstim/Tevagrastim/Biograstim, Zarzio/Filgrastim Hexal and Nivestim/Pliva/Mayne filgrastim. Adding to the G-CSF biosimilars, the insulin biosimilars also showcase tremendous potential in the future.

KEY BENEFITS

  • The study is segmented in a strategic divisions to gain deeper insights into the market dynamics and understand the competitive environment of the overall market
  • Financial market forecast is provided for the next eight years by considering 2013 as the base year
  • Comprehensive and quantitative data about changing market trends, intensifying competition and opportunities in biosimilars market are provided to make better business decisions
  • Porter's Five Forces model and SWOT analysis of the overall market is provided to help stakeholders gain strategic insights of the market
  • Deep dive analysis of key market players and strategies adopted by them are expounded to provide valuable information on the top contenders in the market
  • Identification of key investment pockets for the biosimilars market is strategically dealt to assist the stakeholders

KEY DELIVERABLES

Global biosimilars/follow-on-biologics market is categorized into technology, product types, applications, services and geography.

MARKET BY TECHNOLOGY

  • Monoclonal Antibodies (MAb) Technology
  • Recombinant DNA Technology (rDNA technology)
  • Nuclear magnetic resonance (NMR) technology
  • Chromatography
  • Electrophoresis
  • Mass Spectrometry
  • Western Blotting
  • Bioassay

MARKET BY TYPES

  • Recombinant Non-Glycosylated Protein
    • Human Growth Hormone
    • Insulin
    • Interferon
    • Granulocyte colony stimulating factor (G-CSF)
    • Others
  • Recombinant Glycosylated Protein
    • Erythropoietin
    • Monoclonal antibodies
    • Others
  • Peptides
    • Octreotide
    • Desmopressin
    • Cyclosporine
    • Calcitonin
    • Eptifibatide
    • LH-RH (Leuprolide)
    • Nesiritide
    • Teriparatide
    • Bivalirudin
    • Enfuvirtide
    • Glucagon

MARKET BY APPLICATIONS

  • Blood disorders
    • Chemotherapy induce Anaemia
    • Hemophilia
    • Pulmonary embolism
  • Oncology diseases
    • Lungs cancer
    • Colorectal cancer
    • Breast cancer
    • Cervical cancer
    • Leukemia
    • Prostate cancer
  • Chronic and autoimmune diseases
    • Neutropenia
    • Multiple sclerosis
    • Cystic Fibrosis
    • Rheumatoid arthritis (RA)
    • Acromegaly
    • Leprosy
  • Growth hormone deficiencies
  • Others

MARKET BY SERVICES

  • Contract Research and Manufacturing Services (CRAMS)
  • Clinical Trials

MARKET BY GEOGRAPHY

North America Europe Asia-Pacific LAMEA

Table of Contents

CHAPTER 1 - INTRODUCTION

  • 1.1. Key Benefits
  • 1.2. Key Market Segment
  • 1.3. Key Audiences
    • 1.3.1. Research Methodology
    • 1.3.2. Primary Research
    • 1.3.3. Secondary Research
    • 1.3.4. Analyst tools and models

CHAPTER 2 - EXECUTIVE SUMMARY

  • 2.1. CXO perspective
  • 2.2. Market beyond: what to expect by 2025
    • 2.2.1. Moderate growth scenario
    • 2.2.2. Rapid growth scenario
    • 2.2.3. Diminishing growth scenario

CHAPTER 3 - MARKET OVERVIEW

  • 3.1. Market Definition
  • 3.2. Diverse approach of global regulators towards biosimilars
  • 3.3. Safety issues of biosimilar drugs
  • 3.4. Key Findings
    • 3.4.1. Top factors impacting Biosimilars/Follow-On-Biologics market
    • 3.4.2. Top winning strategies in the Biosimilars/Follow-On-Biologics market
    • 3.4.3. Top investment pockets in Biosimilars/Follow-On-Biologics market
  • 3.5. Regulation and Reimbursement scenario
    • 3.5.1. Regulations in United States
    • 3.5.2. Regulations in Europe
    • 3.5.3. Regulation in Asia
    • 3.5.4. Comparison of Biosimilar medicine guidelines
  • 3.6. Emerging economies a hotspot for biosimilars market
    • 3.6.1. “Brazil” a treasure for the biosimilar manufacturers
    • 3.6.2. “China” the dragon market for biosimilars
    • 3.6.3. “India” an early adopter of biosimilars
  • 3.7. Porters five force analysis
    • 3.7.1. Moderate bargaining of suppliers due to moderate switching cost
    • 3.7.2. Moderate bargaining power of buyers due to lesser cost of switching
    • 3.7.3. Higher threats from substitutes due to lower switching cost
    • 3.7.4. Lower threats from new entrants due to technological and political barriers
    • 3.7.5. Higher competition among players
  • 3.8. Value chain analysis
    • 3.8.1. Primary activities
    • 3.8.2. Impact analysis of stakeholders involved in primary activities (2014-2020)
    • 3.8.3. Supportive activities
  • 3.9. Clinical trials
    • 3.9.1. Title: Efficacy Study of Two Formulations of Erythropoietin
    • 3.9.2. Title: Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anemia in Hematology and Oncology
    • 3.9.3. Title: MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia
    • 3.9.4. Title: An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1
  • 3.10. Market Share analysis, 2013
  • 3.11. Market Dynamics
    • 3.11.1. Drivers
      • 3.11.1.1. Growing pressure to reduce healthcare expenditure
      • 3.11.1.2. Various blockbusters going off patent
      • 3.11.1.3. High prevalence of chronic diseases among ageing population
      • 3.11.1.4. Favorable intervention from the developing economies
      • 3.11.1.5. Lower cost biosimilars drugs than original biologics
    • 3.11.2. Restraints
      • 3.11.2.1. High initial investment in research and development
      • 3.11.2.2. Stringent regulations in developed economies to restrict investment
      • 3.11.2.3. Medical Efficacy and Patient Safety
    • 3.11.3. Opportunities
      • 3.11.3.1. opportunities in Emerging economies
      • 3.11.3.2. Emergence of bio-betters drugs

CHAPTER 4 - GLOBAL BIOSIMILARS/FOLLO-ON-BIOLOGICS MARKET BY TECHNOLOGY

  • 4.1. Monoclonal Antibodies (MAb) Technology
    • 4.1.1. Drivers
  • 4.2. Recombinant DNA Technology (rDNA technology)
    • 4.2.1. Drivers
    • 4.2.2. Restraints & Opportunities
  • 4.3. Chromatography
    • 4.3.1. Drivers & Opportunities
    • 4.3.2. Liquid chromatography (LC)
    • 4.3.3. Gas Chromatography (GC)
    • 4.3.4. Protein sequencing
    • 4.3.5. Drivers
  • 4.4. Nuclear magnetic resonance (NMR) technology
    • 4.4.1. Drivers
  • 4.5. Electrophoresis
    • 4.5.1. Drivers
    • 4.5.2. Restraints & Opportunities
    • 4.5.3. Gel Electrophoresis
    • 4.5.4. Capillary Electrophoresis
  • 4.6. MASS SPECTROMETRY
    • 4.6.1. DRIVERS
    • 4.6.2. RESTRAINTS
  • 4.7. Western Blotting
    • 4.7.1. Drivers
  • 4.8. Bioassay
    • 4.8.1. Drivers
    • 4.8.2. Restraints
    • 4.8.3. Techniques in Bioassay
      • 4.8.3.1. Multiple Point Assays
      • 4.8.3.2. Interpolation Method
      • 4.8.3.3. Bracketing Method
      • 4.8.3.4. Matching Bioassays

CHAPTER 5 - GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY PRODUCT TYPE

  • 5.1. Recombinant Non-Glycosylated Protein
    • 5.1.1. Drivers
    • 5.1.2. Human Growth Hormone
      • 5.1.2.1. Key market trends
      • 5.1.2.2. Key growth factors and opportunities
      • 5.1.2.3. Market size & forecast
    • 5.1.3. Insulin
      • 5.1.3.1. Drivers & Opportunities
      • 5.1.3.2. Key market trends
      • 5.1.3.3. Key growth factors and opportunities
      • 5.1.3.4. Market size & forecast
    • 5.1.4. Interferon
      • 5.1.4.1. Interferon Alfa
      • 5.1.4.2. Interferon beta-1a
      • 5.1.4.3. Interferon gamma
      • 5.1.4.4. Key growth factors and opportunities
      • 5.1.4.5. Market size & forecast
    • 5.1.5. Granulocyte colony stimulating factor (G-CSF)
      • 5.1.5.1. Key market trends
      • 5.1.5.2. Market size & forecast
    • 5.1.6. Others
      • 5.1.6.1. Lepirudin
      • 5.1.6.2. Interleukin - 2 (IL-2)
      • 5.1.6.3. Anakinra
  • 5.2. Recombinant Glycosylated Proteins
    • 5.2.1. Drivers & Restraints
    • 5.2.2. Erythropoietin
      • 5.2.2.1. Key market trends
      • 5.2.2.2. Key growth factors and opportunities
      • 5.2.2.3. Market size & forecast
    • 5.2.3. Monoclonal antibodies
      • 5.2.3.1. Key market trends
      • 5.2.3.2. Key growth factors and opportunities
      • 5.2.3.3. Market size & forecast
    • 5.2.4. Others
      • 5.2.4.1. Follitropin
      • 5.2.4.2. Thyrotropin
      • 5.2.4.3. Urokinase
      • 5.2.4.4. Glucocerebrosidase
      • 5.2.4.5. Becaplermin
      • 5.2.4.6. Factor VIIa
      • 5.2.4.7. Factor VIII
      • 5.2.4.8. Factor IX
    • 5.2.5. Key market trends
    • 5.2.6. Competitive scenario
  • 5.3. Peptide s
    • 5.3.1. Drivers
    • 5.3.2. Restraints & Opportunities
    • 5.3.3. Octreotide
    • 5.3.4. Desmopressin
    • 5.3.5. Cyclosporine
    • 5.3.6. Calcitonin
    • 5.3.7. Eptifibatide
    • 5.3.8. LH-RH (Leuprolide)
    • 5.3.9. Nesiritide
    • 5.3.10. Teriparatide
    • 5.3.11. Bivalirudin
    • 5.3.12. Enfuvirtide
    • 5.3.13. Glucagon

CHAPTER 6 - GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY APPLICATIONS

  • 6.1. Blood disorders
    • 6.1.1. Drivers
    • 6.1.2. Chemotherapy induce Anaemia
      • 6.1.2.1. Drivers
      • 6.1.2.2. RESTRAIN AND OPPORTINITIES
    • 6.1.3. Hemophilia
    • 6.1.4. Pulmonary embolism
      • 6.1.4.1. DRIVER
  • 6.2. Oncology diseases
    • 6.2.1. Driver
    • 6.2.2. Opportunities and restraints
    • 6.2.3. Lungs cancer
    • 6.2.4. Colorectal cancer
    • 6.2.5. Breast cancer
    • 6.2.6. Cervical cancer
    • 6.2.7. Leukemia
      • 6.2.7.1. Drivers
    • 6.2.8. Prostate cancer
  • 6.3. Chronic and autoimmune diseases
    • 6.3.1. Diabetes
      • 6.3.1.1. Drivers
    • 6.3.2. Neutropenia
    • 6.3.3. Multiple sclerosis
      • 6.3.3.1. Drivers
      • 6.3.3.2. Restraints and opportunities
    • 6.3.4. Cystic Fibrosis
    • 6.3.5. Rheumatoid arthritis (RA)
      • 6.3.5.1. Drivers
      • 6.3.5.2. Restraints
    • 6.3.6. Acromegaly
      • 6.3.6.1. Drivers
    • 6.3.7. Leprosy
  • 6.4. Growth hormone deficiency
    • 6.4.1. Drivers
  • 6.5. Others
    • 6.5.1. Gaucher disease
    • 6.5.2. Osteoporosis

CHAPTER 7 - GLOBAL BIOSIMILARS / FOLLOW-ON-BIOLOGICS MARKET BY SERVICES

  • 7.1. Contract Research and Manufacturing Services
    • 7.1.1. Drivers
    • 7.1.2. Restraints & Opportunities
  • 7.2. Clinical trials
    • 7.2.1. Drivers & Restraints
    • 7.2.2. Phase I
    • 7.2.3. Phase II
    • 7.2.4. Phase III

CHAPTER 8 - GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY GEOGRAPHIES

  • 8.1. North America
    • 8.1.1. Key market trends
    • 8.1.2. Key growth factors and opportunities
    • 8.1.3. Market size & forecast
  • 8.2. Europe
    • 8.2.1. Key market trends
    • 8.2.2. Key growth factors and opportunities
    • 8.2.3. Market size & forecast
  • 8.3. Asia-Pacific
    • 8.3.1. Key market trends
      • 8.3.1.1. India
        • 8.3.1.1.1. COMPETITIVE SCENARIO
      • 8.3.1.2. China
        • 8.3.1.2.1. COMPETITIVE SCENARIO
      • 8.3.1.3. Australia
        • 8.3.1.3.1. COMPETITIVE SCENARIO
    • 8.3.2. Market size & forecast
  • 8.4. LAMEA
    • 8.4.1. Key market trends
    • 8.4.2. Competitive scenario
    • 8.4.3. Market size & forecast

CHAPTER 9 - KEY PRODUCTS AND RECENT ACTIVITIES BY GEOGRAPHY

  • 9.1. US
    • 9.1.1. Hospira
      • 9.1.1.1. Recent Activities
  • 9.2. Europe
    • 9.2.1. Stada Arzneimittel AG
      • 9.2.1.1. Recent Activities
    • 9.2.2. Hexal AG
    • 9.2.3. Ratiopharm GmbH
    • 9.2.4. Bioton
      • 9.2.4.1. Recent Activities
    • 9.2.5. Sandoz GmbH
      • 9.2.5.1. Recent Activities
  • 9.3. India
    • 9.3.1. Dr.Reddy's Labs (DRL)
      • 9.3.1.1. Recent Activities
    • 9.3.2. Intas Pharmaceuticals Ltd.
      • 9.3.2.1. Recent Activities
    • 9.3.3. Wockhardt Limited
      • 9.3.3.1. Recent Activities
    • 9.3.4. Biocon Limited
      • 9.3.4.1. Recent Activities
    • 9.3.5. Shantha Biotechnics Limited
      • 9.3.5.1. Recent Activities
    • 9.3.6. Reliance Life Sciences
  • 9.4. Korea
    • 9.4.1. Dong-A Pharmaceutical Co., Ltd
      • 9.4.1.1. Recent Activities
    • 9.4.2. LG Life Sciences
      • 9.4.2.1. Recent Activities
    • 9.4.3. Celltrion Pharm, Inc.
      • 9.4.3.1. Recent Activities
  • 9.5. Others
    • 9.5.1. Teva Pharmaceutical Industries Ltd.
      • 9.5.1.1. Recent Activities

CHAPTER 10 - COMPANY PROFILES

  • 10.1. Novartis (Sandoz)
    • 10.1.1. Company Overview
    • 10.1.2. Company Snapshot
    • 10.1.3. Business Performance
    • 10.1.4. Key Strategies
      • 10.1.4.1. Primary Strategies: Clinical Trials
      • 10.1.4.2. secondary Strategies: approval
    • 10.1.5. SWOT analysis
  • 10.2. Synthon Pharmaceuticals, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Company Snapshot
    • 10.2.3. Key Strategies
      • 10.2.3.1. Primary Strategies: agreement
      • 10.2.3.2. secondary Strategies: clinical trials
    • 10.2.4. SWOT analysis
  • 10.3. Teva Pharmaceutical Industries Ltd.
    • 10.3.1. Company Overview
    • 10.3.2. Company Snapshot
    • 10.3.3. Business Performance
    • 10.3.4. Key Strategies
      • 10.3.4.1. Primary Strategies: approval
      • 10.3.4.2. secondary Strategies: clinical trials
    • 10.3.5. SWOT analysis
  • 10.4. LG Life Sciences
    • 10.4.1. Company Overview
    • 10.4.2. Company Snapshot
    • 10.4.3. Business Performance
    • 10.4.4. Key Strategies
  • 10.4.4.1. Primary Strategies: Collaboration
    • 10.4.5. SWOT analysis
  • 10.5. Celltrion
    • 10.5.1. Company Overview
    • 10.5.2. Company Snapshot
    • 10.5.3. Business Performance
    • 10.5.4. Key Strategies
      • 10.5.4.1. Primary Strategies: approval
    • 10.5.5. SWOT analysis
  • 10.6. Biocon
    • 10.6.1. Company Overview
    • 10.6.2. Company Snapshot
    • 10.6.3. Business Performance
    • 10.6.4. Key Strategies
      • 10.6.4.1. secondary Strategy: clinical trial
    • 10.6.5. SWOT analysis
  • 10.7. Hospira
    • 10.7.1. Company Overview
    • 10.7.2. Company Snapshot
    • 10.7.3. Business Performance
    • 10.7.4. Key Strategies
      • 10.7.4.1. Primary Strategies: approval
      • 10.7.4.2. secondary Strategies: clinical trials
    • 10.7.5. SWOT analysis
  • 10.8. Merck Serono (Merck Group)
    • 10.8.1. Company Overview
    • 10.8.2. Company Snapshot
    • 10.8.3. Business Performance
    • 10.8.4. Key Strategies
      • 10.8.4.1. Primary Strategies: partnership and product launch
    • 10.8.5. SWOT analysis
  • 10.9. Biogen idec Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Company Snapshot
    • 10.9.3. Business Performance
    • 10.9.4. Key Strategies
      • 10.9.4.1. Primary Strategies: agreement and joint venture
    • 10.9.5. SWOT analysis
  • 10.10. Genentech (Roche Group)
    • 10.10.1. Company Overview
    • 10.10.2. Company Snapshot
    • 10.10.3. Key Strategies
      • 10.10.3.1. Primary Strategies: Investment and license
    • 10.10.4. SWOT analysis

LIST OF TABLES

  • TABLE 1: BLOCKBUSTER PATENTS EXPIRATION BY 2014
  • TABLE 2: BIOSIMILARS MODERATE GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
  • TABLE 3: BIOSIMILARS RAPID GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
  • TABLE 4: BIOSIMILARS DIMINISHING GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
  • TABLE 5: BIOSIMILARS GUIDELINES ADOPTED BY REGIONS
  • TABLE 6: COMPARISON OF BIOSIMILAR MEDICINE GUIDELINES BY GEOGRAPHY (2013)
  • TABLE 7: BIOSIMILARS DEVELOPMENT 2013 (LATIN AMERICA)
  • TABLE 8: OFF GOING PATENTS 2013-2016
  • TABLE 9: PREVALENCE OF TOP TWO CHRONIC DISEASES (2013)
  • TABLE 10: BIOSIMILAR DEVELOPMENT STATUS (2013)
  • TABLE 11: GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY PRODUCT TYPES 2013-2020 ($MILLION)
  • TABLE 12: GLOBAL NON-GLYCOSYLATED PROTEIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY PRODUCT TYPES 2013-2020 ($MILLION)
  • TABLE 13: PATENTS STATUS FOR THE HUMAN GROWTH HORMONE (BIOLOGICS)
  • TABLE 14: PATENT EXPIRATION STATUS FOR HUMAN GROWTH HORMONE DURING 2014-2020 (BIOLOGICS)
  • TABLE 15: GLOBAL HGH BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 16: PATENTS APPROVED FOR INSULIN (BIOLOGICS)
  • TABLE 17: GLOBAL INSULIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 18: PATENTS APPROVED FOR INTERFERON (BIOLOGICS)
  • TABLE 19: PATENT EXPIRATION STATUS FOR INTERFERON DURING, 2014-2020 (BIOLOGICS)
  • TABLE 20: GLOBAL INTERFERON BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 21: PATENT EXPIRATION STATUS FOR G-CSF BIOSIMILARS DURING, 2014-2020 (BIOLOGICS)
  • TABLE 22: GLOBAL G-CSF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 23: GLOBAL OTHER NON-GLYCOSYLATED PROTEIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 24: GLOBAL GLYCOSYLATED PROTEIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY PRODUCT TYPES 2013-2020 ($MILLION)
  • TABLE 25: PATENTS STATUS FOR ERYTHROPOIETIN (BIOLOGICS)
  • TABLE 26: PATENT EXPIRATION STATUS FOR ERYTHROPOIETIN DURING 2014-2020 (BIOLOGICS)
  • TABLE 27: GLOBAL ERYTHROPOIETIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 28: DRUG PATENT EXPIRATION FOR MONOCLONAL ANTIBODIES (BIOLOGICS)
  • TABLE 29: PATENT EXPIRATION STATUS FOR MONOCLONAL ANTIBODIES DURING 2014-2020 (BIOLOGICS)
  • TABLE 30: GLOBAL MAB BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 31: GLOBAL OTHER GLYCOSYLATED PROTEIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 32: GLOBAL PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY TYPES 2013-2020 ($MILLION)
  • TABLE 33: GLOBAL OCTREOTIDE PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 34: GLOBAL DESMOPRESSIN PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 35: GLOBAL CYCLOSPORINE PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 36: GLOBAL CALCITONIN PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 37: GLOBAL EPTIFIBATIDE PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 38: GLOBAL LH-RH (LEUPROLIDE)PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 39: GLOBAL NESIRITIDE PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 40: GLOBAL TERIPARATIDE PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 41: GLOBAL BIVALIRUDIN PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 42: GLOBAL ENFUVIRTIDE PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 43: GLOBAL GLUCAGON PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 44: GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS 2013-2020 ($MILLION)
  • TABLE 45: GLOBAL BLOOD DISORDERS BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY2013-2020 ($MILLION)
  • TABLE 46: GLOBAL ONCOLOGY DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY2013-2020 ($MILLION)
  • TABLE 47: GLOBAL CHRONIC AND AUTOIMMUNE DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 48: GLOBAL GROWTH HORMONE DEFICIENCY DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 49: GLOBAL OTHER DISORDERS BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 50: GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
  • TABLE 51: NORTH AMERICA BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 52: EUROPE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2013-2020 ($MILLION)
  • TABLE 53: ASIA-PACIFIC BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2013-2020 ($MILLION)
  • TABLE 54: LAMEA BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2013-2020 ($MILLION)

LIST OF FIGURES

  • FIG. 1: TOP FACTORS IMPACTING BIOSIMILARS MARKET (2013-2020)
  • FIG. 2: TOP WINING STRATEGIES FOR BIOSIMILARS MARKET DURING (2010-2013)
  • FIG. 3: TOP WINING STRATEGIES BY SUBTYPE OF DEVELOPMENTS
  • FIG. 4: TOP INVESTMENT POCKETS OF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET PRODUCTS, 2013-2020
  • FIG. 5: KEY ACHIEVEMENTS FOR BIOSIMILAR REGULATORS (2010)
  • FIG. 6: REGULATORY FRAMEWORK FOR BIOSIMILAR PRODUCTS IN CHINA
  • FIG. 7: PORTER'S FIVE FORCE ANALYSIS OF BIOSIMILARS MARKET
  • FIG. 8: VALUE CHAIN ANALYSIS OF BIOSIMILARS MARKET
  • FIG. 9: MARKET SHARE ANALYSIS OF BIOSIMILARS MARKET (2013)
  • FIG. 10: IMPACT ANALYSIS OF PRODUCT MARKET SEGMENTS (2013-2020-2025)
  • FIG. 11: SALES OF HGH BIOLOGICS IN UNITED STATES 2012
  • FIG. 12: IMPACT ANALYSIS OF APPLICATION MARKET SEGMENTS (2013-2020-2025)
  • FIG. 13: PROJECTED SALES OF EXPIRING PRODUCT IN UNITED STATES
  • FIG. 14: TOP 10 COMPANIES BLOCKBUSTER DRUGS REVENUE IN 2011 AND 2012
  • FIG. 15: NET REVENUE GENERATION BY GEOGRAPHY (2013)
  • FIG. 16: NET REVENUE GENERATION BY BUSINESSES (2013)
  • FIG. 17: SWOT ANALYSIS OF NOVARTIS (SANDOZ)
  • FIG. 18: NET REVENUE GENERATION BY GEOGRAPHY (2013)
  • FIG. 19: NET REVENUE GENERATION BY BUSINESSES (2013)
  • FIG. 20: SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • FIG. 21: NET REVENUE GENERATION (2011-2013)
  • FIG. 22: SWOT ANALYSIS OF LG LIFE SCIENCES
  • FIG. 23: NET PROFIT DURING 2011-2013
  • FIG. 24: SWOT ANALYSIS OF CELLTRION
  • FIG. 25: REVENUE GENERATED BY BUSINESS UNITS (2013)
  • FIG. 26: SWOT ANALYSIS OF BIOCON
  • FIG. 27: NET SALES BY GEOGRAPHY (2013)
  • FIG. 28: NET SALES BY BUSINESS UNITS (2013)
  • FIG. 29: SWOT ANALYSIS OF HOSPIRA
  • FIG. 30: NET SALES BY GEOGRAPHY (2013)
  • FIG. 31: NET SALES BY BUSINESS UNITS (2013)
  • FIG. 32: SWOT ANALYSIS OF MERCK SERONO
  • FIG. 33: NET SALES BY GEOGRAPHY (2013)
  • FIG. 34: NET SALES BY BUSINESS UNITS (2013)
  • FIG. 35: SWOT ANALYSIS OF BIOGEN IDEC INC.
  • FIG. 36: SWOT ANALYSIS OF GENENTECH
Back to Top